212 related articles for article (PubMed ID: 17139369)
1. A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients.
Perry SL; O'Shea SI; Byrne S; Szczech LA; Ortel TL
Thromb Haemost; 2006 Dec; 96(6):750-5. PubMed ID: 17139369
[TBL] [Abstract][Full Text] [Related]
2. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
Douketis J; Cook D; Meade M; Guyatt G; Geerts W; Skrobik Y; Albert M; Granton J; Hébert P; Pagliarello G; Marshall J; Fowler R; Freitag A; Rabbat C; Anderson D; Zytaruk N; Heels-Ansdell D; Crowther M;
Arch Intern Med; 2008 Sep; 168(16):1805-12. PubMed ID: 18779469
[TBL] [Abstract][Full Text] [Related]
3. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
Oldgren J; Johnston N; Siegbahn A
Am Heart J; 2008 Mar; 155(3):493.e1-8. PubMed ID: 18294482
[TBL] [Abstract][Full Text] [Related]
4. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency.
Rabbat CG; Cook DJ; Crowther MA; McDonald E; Clarke F; Meade MO; Lee KA; Cook RJ
J Crit Care; 2005 Dec; 20(4):357-63. PubMed ID: 16310608
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of dalteparin during haemodialysis.
Nigten J; de Groot KA; Grootendorst DC; Koolen SL; Herruer MH; Schut NH
Nephron Clin Pract; 2013; 124(3-4):179-83. PubMed ID: 24401673
[TBL] [Abstract][Full Text] [Related]
6. Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study.
Rommers MK; Van der Lely N; Egberts TC; van den Bemt PM
Crit Care; 2006; 10(3):R93. PubMed ID: 16790078
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of subcutaneous dalteparin in patients with renal insufficiency under intensive care: an observational study.
Kani C; Markantonis SL; Nicolaou C; Maggina N
J Crit Care; 2006 Mar; 21(1):79-84. PubMed ID: 16616629
[TBL] [Abstract][Full Text] [Related]
8. Chrono-pharmacological study of once daily curative dose of a low molecular weight heparin (200 IU antiXa/kg of Dalteparin) in ten healthy volunteers.
Mismetti P; Reynaud J; Tardy-Ponce B; Laporte-Simitsidis S; Scully M; Goodwyn C; Queneau P; Decousus H
Thromb Haemost; 1995 Aug; 74(2):660-6. PubMed ID: 8585003
[TBL] [Abstract][Full Text] [Related]
9. Dalteparin dosing in high-flux haemodialysis and haemodiafiltration.
Sridharan S; Berdeprado J; Sivalingam M; Farrington K
Nephron Clin Pract; 2012; 122(1-2):53-7. PubMed ID: 23548465
[TBL] [Abstract][Full Text] [Related]
10. Intermittent saline flushes during haemodialysis do not alleviate coagulation and clot formation in stable patients receiving reduced doses of dalteparin.
Sagedal S; Hartmann A; Osnes K; Bjørnsen S; Torremocha J; Fauchald P; Kofstad J; Brosstad F
Nephrol Dial Transplant; 2006 Feb; 21(2):444-9. PubMed ID: 16234293
[TBL] [Abstract][Full Text] [Related]
11. Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study.
Tincani E; Mannucci C; Casolari B; Turrini F; Crowther MA; Prisco D; Cenci AM; Bondi M
Haematologica; 2006 Jul; 91(7):976-9. PubMed ID: 16757417
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism).
Collignon F; Frydman A; Caplain H; Ozoux ML; Le Roux Y; Bouthier J; Thébault JJ
Thromb Haemost; 1995 Apr; 73(4):630-40. PubMed ID: 7495071
[TBL] [Abstract][Full Text] [Related]
13. Factor Xa-activated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis.
Frank RD; Brandenburg VM; Lanzmich R; Floege J
Nephrol Dial Transplant; 2004 Jun; 19(6):1552-8. PubMed ID: 15034159
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of the low molecular weight heparin dalteparin in cats.
Mischke R; Schmitt J; Wolken S; Böhm C; Wolf P; Kietzmann M
Vet J; 2012 Jun; 192(3):299-303. PubMed ID: 21978598
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of unfractionated heparin during and after a hemodialysis session.
Brunet P; Simon N; Opris A; Faure V; Lorec-Penet AM; Portugal H; Dussol B; Berland Y
Am J Kidney Dis; 2008 May; 51(5):789-95. PubMed ID: 18436089
[TBL] [Abstract][Full Text] [Related]
16. Tinzaparin versus dalteparin for periprocedure prophylaxis of thromboembolic events in hemodialysis patients: a randomized trial.
Rodger MA; Ramsay T; MacKinnon M; Westphal M; Wells PS; McCormick B; Knoll G
Am J Kidney Dis; 2012 Sep; 60(3):427-34. PubMed ID: 22480794
[TBL] [Abstract][Full Text] [Related]
17. Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention.
Marmur JD; Poludasu S; Feit A; Battala VR; Cavusoglu E
J Invasive Cardiol; 2008 Jul; 20(7):323-7. PubMed ID: 18599887
[TBL] [Abstract][Full Text] [Related]
18. Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease.
Ma JM; Jackevicius CA; Yeo E
Ann Pharmacother; 2004 Oct; 38(10):1576-81. PubMed ID: 15328396
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study.
Klingel R; Schwarting A; Lotz J; Eckert M; Hohmann V; Hafner G
Kidney Blood Press Res; 2004; 27(4):211-7. PubMed ID: 15273423
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man.
Boneu B; Necciari J; Cariou R; Sié P; Gabaig AM; Kieffer G; Dickinson J; Lamond G; Moelker H; Mant T
Thromb Haemost; 1995 Dec; 74(6):1468-73. PubMed ID: 8772222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
